^
    Back
    Association details:
    Biomarker:T-cell-inflamed GEP signature
    Cancer:Renal Cell Carcinoma
    Drug Class:VEGF inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2020
    Title:

    155P - Molecular profiles and response among metastatic renal cell carcinoma patients treated with targeted therapies

    Published date:
    09/14/2020
    Excerpt:
    Angiogenesis and T-cell inflamed GEP gene signatures were associated with response in ccRCC patients receiving VEGF inhibitors. For ccRCC patients, angiogenesis and T-cell inflamed GEP were significantly associated with BOR and PFS (Table).